Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02574078
Title A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate370)
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

lung non-small cell carcinoma

Therapies

Crizotinib + Nivolumab

Erlotinib + Nivolumab

Nivolumab + Pemetrexed Disodium

Bevacizumab

Carboplatin + Pemetrexed Disodium

Bevacizumab + Nivolumab

Nivolumab

Erlotinib

Carboplatin + Paclitaxel

Carboplatin + Docetaxel

Carboplatin + Nab-paclitaxel

Carboplatin + Gemcitabine

Paclitaxel

Docetaxel

Pemetrexed Disodium

Gemcitabine

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.